JP5671618B2 - Pgaを含んでなる新しいemd製剤 - Google Patents
Pgaを含んでなる新しいemd製剤 Download PDFInfo
- Publication number
- JP5671618B2 JP5671618B2 JP2013524463A JP2013524463A JP5671618B2 JP 5671618 B2 JP5671618 B2 JP 5671618B2 JP 2013524463 A JP2013524463 A JP 2013524463A JP 2013524463 A JP2013524463 A JP 2013524463A JP 5671618 B2 JP5671618 B2 JP 5671618B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- pga
- dental
- protein
- kda
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 130
- 238000009472 formulation Methods 0.000 title claims description 115
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 claims description 212
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 claims description 207
- 239000000770 propane-1,2-diol alginate Substances 0.000 claims description 201
- 108090000623 proteins and genes Proteins 0.000 claims description 121
- 102000004169 proteins and genes Human genes 0.000 claims description 119
- 102100040409 Ameloblastin Human genes 0.000 claims description 74
- 101000891247 Homo sapiens Ameloblastin Proteins 0.000 claims description 62
- 210000003298 dental enamel Anatomy 0.000 claims description 58
- 239000002537 cosmetic Substances 0.000 claims description 53
- 239000011159 matrix material Substances 0.000 claims description 47
- 210000001519 tissue Anatomy 0.000 claims description 46
- 238000002360 preparation method Methods 0.000 claims description 42
- 230000001954 sterilising effect Effects 0.000 claims description 34
- 238000004659 sterilization and disinfection Methods 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 238000011069 regeneration method Methods 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 16
- 210000000988 bone and bone Anatomy 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 230000008929 regeneration Effects 0.000 claims description 15
- 108010007570 Amelogenin Proteins 0.000 claims description 13
- 206010052428 Wound Diseases 0.000 claims description 12
- 239000003381 stabilizer Substances 0.000 claims description 12
- 230000017423 tissue regeneration Effects 0.000 claims description 12
- 102000007325 Amelogenin Human genes 0.000 claims description 11
- 208000027418 Wounds and injury Diseases 0.000 claims description 11
- 230000033558 biomineral tissue development Effects 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 230000008733 trauma Effects 0.000 claims description 8
- 230000007547 defect Effects 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 6
- 210000004268 dentin Anatomy 0.000 claims description 6
- 230000008468 bone growth Effects 0.000 claims description 5
- 230000005210 cementogenesis Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 210000004872 soft tissue Anatomy 0.000 claims description 5
- 238000013270 controlled release Methods 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000013268 sustained release Methods 0.000 claims description 4
- 239000012730 sustained-release form Substances 0.000 claims description 4
- 230000000699 topical effect Effects 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 2
- 125000000129 anionic group Chemical group 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 230000001502 supplementing effect Effects 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 110
- 108010074702 enamel matrix proteins Proteins 0.000 description 34
- 150000002148 esters Chemical class 0.000 description 20
- 235000010443 alginic acid Nutrition 0.000 description 19
- 229920000615 alginic acid Polymers 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 229940072056 alginate Drugs 0.000 description 15
- -1 oral suspension Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 150000001413 amino acids Chemical class 0.000 description 13
- 230000007062 hydrolysis Effects 0.000 description 11
- 238000006460 hydrolysis reaction Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000003860 storage Methods 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000003239 periodontal effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229920000084 Gum arabic Polymers 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 229920000954 Polyglycolide Polymers 0.000 description 5
- 235000010489 acacia gum Nutrition 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
- 230000020477 pH reduction Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- 235000013772 propylene glycol Nutrition 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 4
- 206010017076 Fracture Diseases 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 4
- 239000003883 ointment base Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229960005150 glycerol Drugs 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 229940014041 hyaluronate Drugs 0.000 description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 229960004452 methionine Drugs 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000002379 periodontal ligament Anatomy 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 244000043261 Hevea brasiliensis Species 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229940124277 aminobutyric acid Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 239000005312 bioglass Substances 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000008364 bulk solution Substances 0.000 description 2
- 230000011496 cAMP-mediated signaling Effects 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010931 ester hydrolysis Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229940042880 natural phospholipid Drugs 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 210000004417 patella Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 210000001050 stape Anatomy 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 108010022248 tuftelin Proteins 0.000 description 2
- 102000012344 tuftelin Human genes 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- ZDRLKQLULCHOAJ-SECBINFHSA-N (2S)-2-amino-2,3,3-trifluoro-3-(4-hydroxyphenyl)propanoic acid Chemical compound FC([C@](N)(C(=O)O)F)(C1=CC=C(C=C1)O)F ZDRLKQLULCHOAJ-SECBINFHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical group OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WNNNWFKQCKFSDK-BYPYZUCNSA-N (2s)-2-aminopent-4-enoic acid Chemical compound OC(=O)[C@@H](N)CC=C WNNNWFKQCKFSDK-BYPYZUCNSA-N 0.000 description 1
- GTVVZTAFGPQSPC-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-nitrophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-QMMMGPOBSA-N 0.000 description 1
- BWKMGYQJPOAASG-VIFPVBQESA-N (3s)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CN[C@H](C(=O)O)CC2=C1 BWKMGYQJPOAASG-VIFPVBQESA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical class FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- SIQZJFKTROUNPI-UHFFFAOYSA-N 1-(hydroxymethyl)-5,5-dimethylhydantoin Chemical compound CC1(C)N(CO)C(=O)NC1=O SIQZJFKTROUNPI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- NIGWMJHCCYYCSF-QMMMGPOBSA-N 4-chloro-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-QMMMGPOBSA-N 0.000 description 1
- XDOLZJYETYVRKV-UHFFFAOYSA-N 7-Aminoheptanoic acid Chemical compound NCCCCCCC(O)=O XDOLZJYETYVRKV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000008887 Dental Deposits Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XPJVKCRENWUEJH-UHFFFAOYSA-N Isobutylparaben Chemical compound CC(C)COC(=O)C1=CC=C(O)C=C1 XPJVKCRENWUEJH-UHFFFAOYSA-N 0.000 description 1
- CMHMMKSPYOOVGI-UHFFFAOYSA-N Isopropylparaben Chemical compound CC(C)OC(=O)C1=CC=C(O)C=C1 CMHMMKSPYOOVGI-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- UCUNFLYVYCGDHP-UHFFFAOYSA-N L-methionine sulfone Natural products CS(=O)(=O)CCC(N)C(O)=O UCUNFLYVYCGDHP-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000566512 Orthodes Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- PEMUHKUIQHFMTH-UHFFFAOYSA-N P-Bromo-DL-phenylalanine Chemical compound OC(=O)C(N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-UHFFFAOYSA-N 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 201000004328 Pulpitis Diseases 0.000 description 1
- 206010037464 Pulpitis dental Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- XVBRCOKDZVQYAY-UHFFFAOYSA-N bronidox Chemical compound [O-][N+](=O)C1(Br)COCOC1 XVBRCOKDZVQYAY-UHFFFAOYSA-N 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000003477 cochlea Anatomy 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000016674 enamel mineralization Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000002196 fr. b Anatomy 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 210000000540 fraction c Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940113094 isopropylparaben Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003608 radiolysis reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 229910000811 surgical stainless steel Inorganic materials 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/50—Preparations specially adapted for dental root treatment
- A61K6/54—Filling; Sealing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Dental Preparations (AREA)
- Polymers & Plastics (AREA)
- Materials For Medical Uses (AREA)
Description
ALGは、非滅菌のPGAに対して本明細書において使用される略号である。
ALGSは、e−ビームを用いて滅菌した滅菌PGAに対して本明細書で使用される略号である。
1)無菌性の保証水準(SAL)を選択する(10-6);
2)滅菌したサンプルに対する全バイオバーデンを計算する;
3)サンプルはe−ビームを用いて滅菌する;
ことを含む。e−ビーム線量の選択は、ステップ2)の計算を基礎とする。方法はISO規格11137−2(2006)に従う。用語「無菌性の保証水準」は、滅菌後の対象物上における単細胞の生存可能な微生物の発生確率であり、そして用語「バイオバーデン」は、製品の上又は中において生存可能な微生物の個体数である。前記PGAは、粉末として滅菌され、そして得られた製品は無菌環境下で、賦形剤と混合される。あるいは、非滅菌のPGA粉末は、無菌環境下で、賦形剤と混合され、そしてその後、滅菌される。しかし、その他の一般的に公知の滅菌方法も、当業者に知られた通り、非滅菌PGA又は非滅菌PGAを含む混合物を滅菌するために使用することができる。
−送達デバイス、インプラント;
−粉末、顆粒、ペレット、カプセル、アガロース又はキトサンビーズ、微小粒子、ナノ粒子;
−スプレイ、エアゾール、吸入デバイス;
−ゲル、ヒドロゲル、ペースト、軟膏、クリーム、石鹸、歯磨きペースト;
−溶液、分散液、懸濁液、乳化液、混合物、ローション、マウスウオッシュ、シャンプー、浣腸剤;
−例えば、二つの分離した容器を含むキット;
である。ここで、容器の初めの一つが、場合により他の活性薬物物質(一つ又は複数の)及び/又は薬学的に許容可能な賦形剤、担体及び/又は希釈剤と混合した本発明の製剤を含み、そして、第二の容器は、即製の製剤を得るために、使用前に第一の容器に添加する目的の好適な媒体を含む。
FASTA (Altschul, S.F. et al (1990))が挙げられるが、それに限定されない。BLASTXプログラムは、NCBI及び他の出所(BLAST Manual, Altschul, S.F. et al, Altschul, S.F. et al (1990))から、公的に利用可能である。別の好ましい例は、Clustal W (http://www.ebi.ac.uk/clustalw/)である。各々の配列分析のプログラムは、デフォルト・スコアリング・マトリックス及びデフォルト・ギャップ・ペナルティを有する。一般的に、分子生物学者は、使用したソフトウエアプログラムにより確立した初期設定を使用することが期待される。
本発明に記載の、薬学的、歯科的及び/又は化粧品製剤は、硬組織の再生、組織鉱化、骨成長及び/又は骨再成長、象牙質の再生、セメント質形成を促進し及び/又は誘導するため、及び/又は生鉱化組織の部分間を結合、他の一部の生組織上の結合サイトに一部の生鉱化組織を結合させるため;硬組織間の結合を支持するため;及び/又は処置及び/又は外傷から続く鉱化した創腔及び/又は組織欠損を補うため、に使用できる。
〔実施例1〕
質量平均分子量(Mw):
質量平均分子量は、GPC(Agilent社製)を用いたAM−S01分析法に基づいて決定し、そしてパラメータは下記の通りであった:
溶出液:リン酸塩緩衝液:pH7,0;
プレカラム:PSS Suprema:10μm:100Å:8×50mm;
PSS Suprema:10μm:100Å:8×300mm;
PSS Suprema:10μm:1000Å:8×300mm;
PSS Suprema:10μm:100Å:8×300mm;
ポンプ:Agilent1100;
流速:1.0ml/min;
自動サンプラ:Agilent1100、5ομl:注入体積付き;
サンプル濃度:2.0、3.0g/L;
温度:23℃;
検出器:Aglient1100R1;
計算:PSS WinGPC Unity 7.20版;
計算はポルランのモル質量基準を用いた従来の検量線を基礎とした。
Emdogain製剤で使用した滅菌PGAは、ISO−1137−2(2006)基準に基づき、非滅菌PGAのe−ビーム滅菌から得られた。滅菌法は、次のステップを含む:
1.無菌性保証水準(SAL)10-6(百万分の一)が、PGAの一滅菌ユニットに適用される(100gPGA/ポーチ);
2.全バイオバーデンは、この滅菌ユニット(100gPGA/ポーチ) に対して計算される:全バイオバーデン=100g*CFU/g −→ この滅菌ユニットが、例えば、50gPGAのみのパッキングを変更する場合、全バイオバーデンは減少する;
3.従って、この全バイオバーデンVDmax25が適用され −→最小25kGy。
(T.Q Nguyen, H.H Kausch, J. App. Polym. Sci. 29(1984), p.455) ;
(A. Schiltz, et al, Revue Phys. Appl. 19(1984)439 (439-444))
PGAの分解は、C.J. Gray. A. J. Griffiths, D. L. Stevenson, J. F. Kennedy; Studies on the Chemical Stability of Propylene Glycol alginates Ester, Carbohydrate Polymers, 1990, 12, 419-430により研究された。彼らは二つのタイプの分解を同定した:
1)カルボン酸とプロピレングリコールを提供するエステル結合の加水分解(pHの変化);
2)粘度の低下を伴う多糖類骨格におけるグリコシド結合の分解。
モデルを擬一次反応速度式に簡略化するために(式4から式5へ)、エステル濃度[エステル]は、反応速度定数kAと合体させる。Emdogainの安定性の手順において(Biora STP記録)、エステル濃度には従わない。式4が式5に転換したときの同様の考察に従って、エステル濃度の変化は、桁が変わるほど広がっていかないので、それは滅菌PGA濃度[滅菌PGA]により代替できる。
pH低下に及ぼす温度の影響は明らかである。Straumann(登録商標)Emdogainの昇温への曝露は、pH低下の全速度を著しく加速させる。反応速度定数(k”)は、Arrhenius式に基づき、温度(T)により変化し:
EMD製剤の貯蔵安定性:
サンプル調整:
EMD溶液;
濃度33mg/mlを有するEMD溶液は、正規のEMDバルク溶液製造に基づき正規の製造ラインで調製した。溶液は滅菌濾過の後、製造ラインから取り出した。EMD溶液は酢酸及び水を含み、そして溶液のpHは4.9〜5の間であった。
PGA:
Kelcoloid(登録商標)Oは、FMC Biopolymer社から購入した。分子量は既に上記の通り分析した。得られたMw値は上記の表1に示した。PGAは、e−ビーム滅菌で滅菌した。使用装置:Sterigenics:San Diego;送達したe−ビーム線量:25〜30kGy。得られた滅菌PGAは、Mw=184kDa±12kDaを有していた。
Emdoqainサンプルの調製:
得られた滅菌PGA(30.0g)は、層流の空気層(LAF)で、常温(約20℃)の条件下で、EMDバルク溶液(500mL)に徐々に加えた。溶液を撹拌し、撹拌は24時間継続し、その後、停止した。Emdoqain製剤サンプルは、LAFの条件下で滅菌サンプル管(50mL)内に移送した。一サンプルを引出し、pH及び粘度を測定した:
粘度=3.0Pa・s(22℃、18.9:1/s)(Anton Paar MRC Physica−300レオメータ、構成:CP-25-2 --> シリアル番号:12513):
pH=4.70(Metrohm780:pH meter:Entrich pH プローブ番号:6.00226.100装備付き)。
得られたサンプルは、調製後、速やかに冷蔵庫に置いた。冷蔵庫の温度は、+4℃に調節した。温度はサンプルの近辺で制御した。温度のずれは、±2.0℃を超えなかった。
サンプルのpHは、14ヶ月間測定した(図9参照)。
対照サンプル:
pHの安定性データは、Emdogain安定性プログラムから誘導した。データは、e−ビーム滅菌PGA:Mw=117kDaを用いて調製したEmdogainサンプルから選択した。
対照サンプルの名称は、E7254であり:
初期値:粘度:3.0Pa・s(22℃、18.9:1/s)及びpH4.5;
粗製PGA:Mw=219kDa;
滅菌 (e−ビーム処理)PGA:Mw=17kDa;
対照サンプルのpHは24ヶ月間測定した(図9参照)。
1. Gestrelius S, Lyngstadaas SP, Hammarstrom L. Emdogain − periodontal;
regeneration based on biomimicry. Clin Oral Invest 4: 120-125 (2000);
2. Hammarstrom et al., 1997, Journal of Clinical Periodontology 24, 658-668;
3. Lyngstadaas et al., 2001 , Journal of Clinical Periodontology 28, 181-188;
4. US 467032;
5. EP-B-0 337 967;
6. EP-B-0 263086;
7. EP-B-1059934;
8. EP-B-1 153610;
9. WO 01/97834;
10. WO 00/53197;
11. WO 00/53196;
12. WO 03/024479;
13. WO 02/080994;
14. US 5098891;
15.D.J. McHuah - HYPERLINK http://www.fao.org/docrep/x5822e/x5822e04.htm;
16. Svensson J, Andersson C, Reseland JE, Lyngstadaas SP, Bulow L. Histidine tag fusion increase expression levels of active recombinant Amelogenin in Escherichia coli. Protein Expr Purif, 48; 134-41 (2006);
17. C.J. Gray. A. J. Griffiths, D. L. Stevenson, J. F. Kennedy; Studies on the
Chemical Stability of Propylene Glycol alginates Ester, Carbohydrate Polymers, 1990, 72, 419- 430;
18. T.Q Nguyen, H.H Kausch, J. App. Polym. Sci. 29 (1984), p.455-464; A. Schiltz, et al, Revue Phys. Appl. 19 (1984) 439 (439-444);
19. Hammarstrom et al., “Periodontal regereration in a buccal dehiscene model
in monkeys after application of enamel matrix proteins”, J Clin Periodontol 1997 (24)669-677;
20. Lyngstadaas el al., “Enamel matrix proteins; old molecules for new applications”, Orthod Craniofac Res 2009 August 12(3) 243-253;
21. US 20060147395 A1;
22. EP-A2-1 120428;
23. Gestrelius et al., “Formulation of enamel matrix derivative for surface coatings”, J Clin Periodontol 1997 (24) 678-684; Heijl et al., J Clin Periodonol
1997 (24) 693-696;
Claims (25)
- エナメル基質蛋白質及び/又はエナメル基質誘導体(EMD)を含んでなる、薬学的、歯科的及び/又は化粧品製剤であって、6質量/体積%(w/v%)以下の滅菌プロピレングリコールアルギナート(PGA)を含み、そしてここで、該滅菌PGAは、130kDaを超える質量平均分子量(Mw)を有する、上記製剤。
- 滅菌PGAの質量平均分子量が、130〜250kDaの間の範囲内にある、請求項1に記載の薬学的、歯科的及び/又は化粧品製剤。
- 130kDaを超える質量平均分子量を有し、3質量/体積%(w/v%)〜6質量/体積%(w/v%)の範囲内の滅菌PGAを含んでなる、請求項1又は2に記載の薬学的、歯科的及び/又は化粧品製剤。
- 滅菌PGAの質量平均分子量が135kDaを超えるか又はそれに等しい、請求項1〜3のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。
- 滅菌PGAの質量平均分子量(Mw)が、185kDaを超えるか又はそれに等しい、請求項1〜4のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。
- 滅菌プロピレングリコールアルギナートが、少なくとも250kDaの初期質量平均分子量(Mwo)を有する非滅菌PGAのe−ビーム滅菌より得られる、請求項1〜5のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。
- 滅菌PGAが、250〜500kDaの範囲内の初期質量平均分子量(Mwo)を有する非滅菌PGAのe−ビーム滅菌より得られる、請求項6に記載の薬学的、歯科的及び/又は化粧品製剤。
- 適用されるe−ビーム滅菌線量が、25〜30kGyの範囲の線量から選ばれる、請求項6又は7に記載の薬学的、歯科的及び/又は化粧品製剤。
- エナメル基質蛋白質及び/又はエナメル基質誘導体(EMD)蛋白質は、18〜25kDaの間、20〜24kDaの間、20〜22kDaの間、及び20kDaから成るグループから選択される平均分子量を有する、少なくとも60〜70%アメロゲニンを含む、請求項1〜8のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。
- 前記製剤が少なくとも18ヶ月に亘って、3.5を超えるpHを有する、請求項1〜9のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。
- 前記製剤が24ヶ月の期間に亘って、3.5を超えるpHを有する、請求項1〜10のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。
- 前記製剤が2〜8℃の温度範囲で、3.5を超えるpHを有する、請求項10又は11に記載の薬学的、歯科的及び/又は化粧品製剤。
- 製剤が、更に、一つ又はそれ以上の薬学的に許容可能な賦形剤、薬学的に許容可能な一つ又は複数の担体又はそれらの組合せを含む、請求項1〜12のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。
- エナメル基質蛋白質及び/又はエナメル基質誘導体(EMD)蛋白質の量が、その基質蛋白質及び/又はエナメル基質誘導体(EMD)蛋白質及び滅菌PGAの全組合せ質量で、その他の賦形剤を含まない質量に基づいて、93%〜98%、94%〜97%、及び95%〜96%(質量/体積)の範囲内である、請求項1〜13のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。
- 更に、一つ又はそれ以上の非エナメル基質蛋白質及び/又はエナメル基質誘導体(EMD)蛋白質活性剤を含んでなる、請求項1〜14のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。
- 少なくとも二つの表面安定剤を含んでなる、請求項1〜15のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。
- 表面安定剤が、アニオン表面安定剤、カチオン表面安定剤、両性イオン表面安定剤及びイオン性安定剤から成るグループから選択される、請求項1〜16のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。
- 医療において使用するための、請求項1〜17のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。
- 製剤が、経口、肺内、直腸、眼内、結腸、非経口、大そう内、膣内、腹腔内、局所、頬内、鼻腔内及び局所投与から成るグループから選択される投与用に製剤化される、請求項1〜18のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。
- 液体分散剤、経口懸濁剤、ゲル剤、エアゾール剤、軟膏剤、クリーム剤、放出制御製剤ファーストメルト製剤、凍結乾燥製剤、錠剤、カプセル剤、遅延放出製剤、持続放出製剤、パルス放出製剤、及び混合型即時放出及び制御放出製剤より成るグループから選択した投薬形態に製剤化される、請求項1〜19のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。
- 硬組織の再生、組織鉱化、骨成長及び/又は骨再成長、象牙質の再生、セメント質形成
を促進し及び/又は誘導するのに、及び/又は生鉱化組織の部分間を結合するのに使用するため;他の一部の生組織上の結合サイトに一部の生鉱化組織を結合させるため;硬組織間の結合を支持するため;及び/又は処置及び/又は外傷から続く鉱化した創腔及び/又は組織欠損を補うため;の、請求項1〜20のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。 - 軟組織の再生を促進し及び/又は誘導するのに使用するため、及び/又は炎症及び/又は感染症を処置し及び/又は予防するため、及び/又はSIRSを処置するため;硬組織の再生、組織鉱化、骨成長及び/又は骨再成長、象牙質の再生、セメント質形成を促進し及び/又は誘導するため、及び/又は生鉱化組織の部分間を結合するため;一部の生鉱化組織を他の一部の生組織上の結合サイトに結合させるため;硬組織間の結合を支持するため;及び/又は処置及び/又は外傷から続く鉱化した創腔及び/又は組織欠損を補うため;の、請求項1〜21のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤。
- 軟組織の再生を促進し及び/又は誘導するため:及び/又は炎症及び/又は感染症の処置及び/又は予防のため;及び/又はSIRSの処置のため;硬組織の再生、組織鉱化、骨成長及び/又は骨再成長、象牙質の再生、セメント質形成を促進し及び/又は誘導するため、及び/又は生鉱化組織の部分間を結合するため;一部の生鉱化組織を他の一部の生組織上の結合サイトに結合させるため;硬組織間の結合を支持するため;及び/又は処置及び/又は外傷から続く鉱化した創腔及び/又は組織欠損を補うため;の薬学的組成物の製造のための、請求項1〜22のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤の使用。
- 請求項1〜23のいずれか1項に記載の薬学的、歯科的及び/又は化粧品製剤を製造する方法であって、次の:
a. 発育期の哺乳類の歯から、エナメル基質蛋白質及び/又はエナメル基質誘導体(EMD)蛋白質を単離する工程;
b. 250kDaを超える初期質量平均分子量(Mwo)を有する非滅菌PGAを25〜30kGyの範囲の線量でe−ビーム滅菌する工程;及び
c. a.から得られた生産物とb.から得られた生産物とを混合する工程;
を含んでなることを特徴とする、上記方法。 - エナメル基質蛋白質及び/又はエナメル基質誘導体(EMD)蛋白質、及び130kDaを超える質量平均分子量を有する滅菌プロピレングリコールアルギナート(PGA)を含んでなる、薬学的、歯科的及び/又は化粧品製剤であって、ここで、該製剤が次の:
a. 発育期の哺乳類の歯から、エナメル基質蛋白質及び/又はエナメル基質誘導体(EMD)蛋白質を単離する工程;
b. 250〜500kDaの範囲の初期質量平均分子量(Mwo)を有する非滅菌PGAを25〜30kGyの範囲の線量でe−ビーム滅菌する工程;及び
c. a.から得られた生産物とb.から得られた生産物とを混合する工程;
を含んでなる方法により製造される、上記製剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1051082-4 | 2010-10-15 | ||
SE1051082 | 2010-10-15 | ||
PCT/EP2011/068092 WO2012049324A2 (en) | 2010-10-15 | 2011-10-17 | New emd formulation comprising pga |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013534240A JP2013534240A (ja) | 2013-09-02 |
JP5671618B2 true JP5671618B2 (ja) | 2015-02-18 |
Family
ID=44883221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013524463A Active JP5671618B2 (ja) | 2010-10-15 | 2011-10-17 | Pgaを含んでなる新しいemd製剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9789190B2 (ja) |
EP (1) | EP2566504B1 (ja) |
JP (1) | JP5671618B2 (ja) |
KR (1) | KR101821842B1 (ja) |
CN (1) | CN103153334B (ja) |
CA (1) | CA2801332C (ja) |
WO (1) | WO2012049324A2 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI709570B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析法及製法 |
TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
ES2708976T3 (es) * | 2014-01-17 | 2019-04-12 | Straumann Holding Ag | Procedimiento para producir EMD de estabilidad aumentada |
EP3166629B1 (en) | 2014-07-09 | 2019-04-24 | Straumann Holding AG | Low viscosity emd |
EP3843869A1 (en) * | 2018-08-31 | 2021-07-07 | Genzyme Corporation | Sterile chromatography resin and use thereof in manufacturing processes |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US467032A (en) | 1892-01-12 | Side apron for vehicles | ||
US4672032A (en) | 1983-11-09 | 1987-06-09 | University Of Southern California | Dental enamel production |
SE454480B (sv) | 1986-09-25 | 1988-05-09 | Lars Hammarstrom | Bindningsinducerande komposition |
SE461313B (sv) | 1988-03-17 | 1990-02-05 | Biora Ab | Bindningsinducerande komposition |
JPH0690703A (ja) * | 1992-09-09 | 1994-04-05 | Sumitomo Metal Ind Ltd | 抗潰瘍性食品 |
EP1153610B1 (en) | 1998-02-27 | 2003-08-20 | Biora Bioex AB | Matrix protein compositions for inflammatory and infectious conditions |
US6503539B2 (en) * | 1998-02-27 | 2003-01-07 | Biora Bioex Ab | Matrix protein compositions for wound healing |
AU2821200A (en) | 1999-03-10 | 2000-09-28 | Biora Bioex Ab | Matrix protein compositions for grafting |
JP2002538211A (ja) | 1999-03-10 | 2002-11-12 | バイオラ バイオエクス エービー | アポトーシスを誘導するためのマトリックスタンパク質組成物 |
KR100721752B1 (ko) | 2000-01-24 | 2007-05-25 | 쿠라레 메디카루 가부시키가이샤 | 수팽윤성 고분자 겔 및 그 제조법 |
AR030557A1 (es) | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
DE60140191D1 (de) | 2000-06-20 | 2009-11-26 | Straumann Inst Ag | Zusammensetzungen mit matrixproteinen zur regeneration von dentin |
WO2002080994A1 (en) | 2001-02-23 | 2002-10-17 | Biora Bioex Ab | Matrix protein compositions for guided connective tissue growth |
MXPA04002348A (es) | 2001-09-14 | 2004-09-28 | Biora Bioex Ab | Composiciones de proteina de matriz de esmalte para modular respuesta inmune. |
SE0403014D0 (sv) | 2004-12-10 | 2004-12-10 | Straumann Holding Ag | New protein formulation |
CA2589095C (en) * | 2004-12-10 | 2012-05-08 | Straumann Holding Ag | Protein formulation for administering an active enamel substance |
EP1862170B1 (en) | 2004-12-10 | 2012-03-14 | Straumann Holding AG | Enamel formulation with amelogenin |
SE531318C2 (sv) * | 2007-02-22 | 2009-02-24 | Tigran Technologies Ab Publ | Injicerbar suspension innefattande titan-,titanlegerings- eller titanoxidpartiklar av mikrostruktur |
EP2162531B1 (en) * | 2007-05-04 | 2019-01-16 | Ascendia AB | Method and means for culturing osteoblastic cells |
-
2011
- 2011-10-17 WO PCT/EP2011/068092 patent/WO2012049324A2/en active Application Filing
- 2011-10-17 CA CA2801332A patent/CA2801332C/en active Active
- 2011-10-17 JP JP2013524463A patent/JP5671618B2/ja active Active
- 2011-10-17 EP EP11773444.2A patent/EP2566504B1/en active Active
- 2011-10-17 CN CN201180032934.8A patent/CN103153334B/zh active Active
- 2011-10-17 KR KR1020137003378A patent/KR101821842B1/ko active IP Right Grant
- 2011-10-17 US US13/643,658 patent/US9789190B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2566504B1 (en) | 2016-11-30 |
KR20130119909A (ko) | 2013-11-01 |
CN103153334B (zh) | 2016-11-16 |
CN103153334A (zh) | 2013-06-12 |
US20130210735A1 (en) | 2013-08-15 |
KR101821842B1 (ko) | 2018-01-24 |
JP2013534240A (ja) | 2013-09-02 |
US9789190B2 (en) | 2017-10-17 |
WO2012049324A2 (en) | 2012-04-19 |
CA2801332A1 (en) | 2012-04-19 |
WO2012049324A3 (en) | 2012-06-28 |
CA2801332C (en) | 2016-08-23 |
EP2566504A2 (en) | 2013-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5671618B2 (ja) | Pgaを含んでなる新しいemd製剤 | |
EP1292325B1 (en) | Matrix protein compositions for dentin regeneration | |
EP2118136B1 (en) | Consensus peptide | |
US20230082131A1 (en) | Compositions including amelogenin and uses thereof | |
JP5047323B2 (ja) | 生理活性ペプチド及びこれを含有する薬剤 | |
JP6483139B2 (ja) | 増強した安定性のemdの製造方法 | |
US7304030B2 (en) | Matrix protein composition for dentin regeneration | |
AU2011315454A1 (en) | New EMD formulation comprising PGA | |
WO2001097835A1 (en) | Matrix protein compositions for inhibition of epithelial cell growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130214 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140325 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140623 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141125 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141219 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5671618 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |